Low-Dose Rate Brachytherapy for Patients with Low- or Intermediate-Risk Prostate Cancer

This is a clinical practice guideline for patients with newly diagnosed low- or intermediate-risk prostate cancer who require or choose active treatment and are not considering or are not suitable for active surveillance. The guideline discusses treatment of prostate cancer with low-dose rate brachytherapy (LDR-BT), and comparisons of LDR-BT treatment alone are made to external beam therapy (EBRT) alone, radical prostatectomy (RP) alone, and LDR-BT combined with EBRT. Different isotope options for LDR-BT are also discussed. Outcomes of interest include biochemical relapse-free and overall survival, prostate cancer-specific and overall mortality, negative biopsy rate, salvage treatment rate, toxicity, and quality of life.